Archit Organosys Approves 92.2% Archit Life Science Acquisition Via Share Swap

Board approved preferential issue of up to 3.72 Cr shares at Rs 65 each, via share swap, to acquire 92.2% of Archit Life Science; authorised capital raised to Rs 60 Cr, subject to approvals. First equity dilution since listing and a return to control of the former subsidiary; shifts the company toward acquisition-led expansion and promoter/non-promoter share issuance. No cash proceeds are raised; substantial dilution and related-party governance require scrutiny. Target performance, integration benefits and final approvals remain unresolved.